[go: up one dir, main page]

MX2010010876A - Piperidinas sustituidas como compuestos terapeuticos. - Google Patents

Piperidinas sustituidas como compuestos terapeuticos.

Info

Publication number
MX2010010876A
MX2010010876A MX2010010876A MX2010010876A MX2010010876A MX 2010010876 A MX2010010876 A MX 2010010876A MX 2010010876 A MX2010010876 A MX 2010010876A MX 2010010876 A MX2010010876 A MX 2010010876A MX 2010010876 A MX2010010876 A MX 2010010876A
Authority
MX
Mexico
Prior art keywords
therapeutic compounds
substituted piperidines
compounds
piperidines
substituted
Prior art date
Application number
MX2010010876A
Other languages
English (en)
Inventor
Peter Herold
Robert Mah
Stefan Stutz
Aleksandar Stojanovic
Dirk Behnke
Vincenzo Tschinke
Stjepan Lakovic
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2010010876A publication Critical patent/MX2010010876A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06Antimalarials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Se describen compuestos de la fórmula general (1): (ver fórmula (I)) y la sal farmacéuticamente aceptable de los mismos, en donde R1 tiene las definiciones ilustradas con detalle en la descripción, como inhibidores de beta-secretasa, catepsina D, plasmepsina II, y/o proteasa de VIH.
MX2010010876A 2008-04-02 2009-04-01 Piperidinas sustituidas como compuestos terapeuticos. MX2010010876A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08153929 2008-04-02
PCT/EP2009/053898 WO2009121914A1 (en) 2008-04-02 2009-04-01 Substituted piperidines as therapeutic compounds

Publications (1)

Publication Number Publication Date
MX2010010876A true MX2010010876A (es) 2010-10-26

Family

ID=40627638

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010010876A MX2010010876A (es) 2008-04-02 2009-04-01 Piperidinas sustituidas como compuestos terapeuticos.

Country Status (10)

Country Link
EP (1) EP2271644A1 (es)
JP (1) JP2011516453A (es)
KR (1) KR20110002459A (es)
CN (1) CN101970431A (es)
AU (1) AU2009232012A1 (es)
BR (1) BRPI0910991A2 (es)
CA (1) CA2719070A1 (es)
EA (1) EA201001517A1 (es)
MX (1) MX2010010876A (es)
WO (1) WO2009121914A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011057160A2 (en) * 2009-11-06 2011-05-12 The Regents Of The Uiversity Of California Method to improve the immunogenicity of vaccine antigens by modification of cleavage sites in hiv-1 gp 120
BR112012008849A2 (pt) 2009-10-14 2015-09-22 Schering Corp composto, composição farmacêutica, e, uso de um composto
GB201008209D0 (en) * 2010-05-17 2010-06-30 Senexis Ltd Compounds
EP2771008A4 (en) 2011-10-28 2015-04-08 Merck Sharp & Dohme MACROCYCLES FOR INCREASING P53 ACTIVITY AND USES THEREOF
TW201429969A (zh) 2012-12-20 2014-08-01 Merck Sharp & Dohme 作爲hdm2抑制劑之經取代咪唑吡啶
CN105001300A (zh) * 2014-04-17 2015-10-28 复旦大学 组织蛋白酶d抑制剂及其制备方法、药物组合物和应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1816122A3 (en) * 2006-01-19 2007-09-19 Speedel Experimenta AG 3,4,5-substituted piperidines as therapeutic compounds
EP1911758A1 (en) * 2006-10-04 2008-04-16 Speedel Experimenta AG Phenyl piperidine derivatives for use as renin inhibitors
EP1908761A1 (en) * 2006-10-04 2008-04-09 Speedel Experimenta AG Organic compounds

Also Published As

Publication number Publication date
AU2009232012A1 (en) 2009-10-08
JP2011516453A (ja) 2011-05-26
CN101970431A (zh) 2011-02-09
EP2271644A1 (en) 2011-01-12
BRPI0910991A2 (pt) 2016-01-19
WO2009121914A1 (en) 2009-10-08
CA2719070A1 (en) 2009-10-08
KR20110002459A (ko) 2011-01-07
EA201001517A1 (ru) 2011-04-29

Similar Documents

Publication Publication Date Title
UA106748C2 (uk) Похідні проліну як інгібітори катепсину
EA201070786A1 (ru) Бензофуропиримидиноны
MY153915A (en) Organic compounds
CL2016002589A1 (es) Uso del compuesto genz-112638 (eliglustat), inhibidor de glucosilceramida sintasa, en el tratamiento de la enfermedad de gaucher y enfermedad de fabry (divisional de solicitud 201201348).
MX2012006805A (es) Indolil-piperidinil bencilaminas como inhibidores de beta-triptasa.
MX2010008523A (es) Inhibidores macrociclicos de serina proteasa.
TW200740776A (en) N-phenylbenzotriazolyl c-kit inhibitors
MX2007011023A (es) 2-(4-oxo-4h-quinazolin-3-il) acetamidas y su uso como antagonistas de vasopresin v3.
NO20091395L (no) Nye tiofenderivater
MX2010006738A (es) Inhibidores de proteasa del virus de la hepatitis c (hcv) y usos de los mismos.
MX2010006736A (es) Inhibidores de proteasa del virus de la hepatitis c (hcv) y usos de los mismos.
MX2011011854A (es) Dihidropirimidinonas para uso como inhibidores de la bace2.
IN2012DN01233A (es)
EA201170521A1 (ru) Новые соединения
TNSN08191A1 (en) Kinase inhibitors
PT2310356E (pt) Derivados de adamantildiamida e a sua utilização
MY153921A (en) Aminopyrazole derivatives
TW200833324A (en) Sulfonamide derivatives
MY140514A (en) Triazolopyridine derivatives as inhibitors of lipases and phospholipases
EA201270590A1 (ru) Ингибиторы акт
TW200722421A (en) Azole derivatives as inhibitors of lipases and phospholipases
MX2010009927A (es) Derivados de espiroindolinona.
ATE531721T1 (de) Cyanoaminochinolone als gsk-3-inhibitoren
MX2010010876A (es) Piperidinas sustituidas como compuestos terapeuticos.
NO20081292L (no) Pentasykliske kinaseinhibitorer

Legal Events

Date Code Title Description
FA Abandonment or withdrawal